At Perlmutter Cancer Center, Clinical Trials Office staff perform specific roles to assist investigators in conducting cancer-related clinical trials. This includes providing support for designing and implementing clinical trials, monitoring safety and compliance, and reviewing, approving, or rejecting trial protocols, as well as the clinical coordination of cancer clinical trials and data management services.

Our Disease Management Groups (DMGs) meet at least monthly to design and implement new clinical and translational research initiatives and investigator-initiated and early phase trials. They also prioritize clinical protocols for submission to the Protocol Review and Monitoring Committee (PRMC).

A team of physicians, program managers, regulatory specialists, and research coordinators provides Perlmutter Cancer Center researchers with the support they need to run clinical trials.

Breast Cancer Research
Endocrine Cancer Research
Gastrointestinal Cancer Research
Genitourinary Cancer Research
Gynecologic Oncology Research
Head and Neck Cancer Research
Hematologic Malignancies Research
Melanoma Research
Neurologic Oncology Research
Pediatric Oncology Research
Phase I Clinical Trials Unit
Sarcoma Research
Thoracic Oncology Research

Breast Cancer Disease Management Group

Learn more about the Breast Cancer DMG.

Clinical Trials Office Program Manager

Please contact Ethel Yepes at Ethel.Yepes@NYULangone.org.

Endocrine Cancer Disease Management Group

Learn more about the Endocrine Cancer DMG.

Clinical Trials Office Program Manager

Please contact Christopher Infantino at Christopher.Infantino@NYULangone.org

Gastrointestinal Cancer Disease Management Group

Learn more about the Gastrointestinal Cancer DMG.

Clinical Trials Office Program Manager

Please contact Monica Dureja at Monica.Dureja@NYULangone.org.

Genitourinary Cancer Disease Management Group

Learn more about the Genitourinary Cancer DMG.

Clinical Trials Office Program Manager

Please contact Sarah Griglun at Sarah.Griglun@NYULangone.org.

Gynecologic Oncology Disease Management Group

Learn more about the Gynecologic Oncology DMG.

Clinical Trials Office Program Manager

Please contact Keith Kallas at Keith.Kallas@NYULangone.org.

Head and Neck Cancer Disease Management Group

Learn more about the Head and Neck Cancer DMG.

Clinical Trials Office Program Manager

Please contact Christopher Infantino at Christopher.Infantino@NYULangone.org.

Hematologic Malignancies Disease Management Group

Learn more about the Hematologic Malignancies DMG.

Clinical Trials Office Program Manager

Please contact Antoine Mesidor at Antoine.Mesidor@NYULangone.org.

Melanoma Disease Management Group

Learn more about the Melanoma DMG.

Clinical Trials Office Program Manager

Please contact Christopher Infantino at Christopher.Infantino@NYULangone.org.

Neurologic Oncology Disease Management Group

Learn more about the Neurologic Oncology DMG.

Clinical Trials Office Program Manager

Please contact Keith Kallas at Keith.Kallas@NYULangone.org.

Pediatric Oncology Disease Management Group

Learn more about the Pediatric Oncology DMG.

Clinical Trials Office Program Manager

Please contact Anna Yaffe at Anna.Yaffe@NYULangone.org.

Phase I Clinical Trials Unit

Program Manager

Please contact Peter Warren at Peter.Warren@NYULangone.org.

Sarcoma Disease Management Group

Learn more about the Sarcoma DMG.

Clinical Trials Office Program Manager

Please contact Christopher Infantino at Christopher.Infantino@NYULangone.org.

Thoracic Oncology Disease Management Group

Learn more about the Thoracic Oncology DMG.

Clinical Trials Office Program Manager

Please contact Rachael Keller at Rachael.Keller@NYULangone.org.

Data and Safety Monitoring Committee

The Data and Safety Monitoring Committee monitors safety, conduct, and compliance with protocol data and trial safety monitoring plans for cancer clinical trials that are not monitored by any other institution or agency.

We review phase 0, phase I, phase II, phase I/II, and phase III studies that are Perlmutter Cancer Center investigator–initiated protocols and National Cancer Institute (NCI) protocols that are not monitored by the NCI. We also review multicenter phase 0, I, II, and III clinical trials with data coordination at Perlmutter Cancer Center.

Program Coordinator

Please contact Nancy Pollas at Nancy.Pollas@NYULangone.org.

Internal Audit Committee

The Internal Audit Committee conducts quality assurance audits quarterly and biannual audits of all Perlmutter Cancer Center studies. The committee includes one physician chair, nurses, and clinical trials office management staff. Perlmutter Cancer Center’s biostatistics shared resource randomly selects at least 10 percent of subjects enrolled in the past 6 months to be audited, and at least one study per DMG. Designated reviewers review each subject chart with regards to the following elements:

• informed consent process
• screening and eligibility
• protocol compliance with regards to treatment, reporting of adverse events, and study procedures
• Case Report Form (CRF) data quality
• regulatory compliance

Protocol Review and Monitoring Committee

The Protocol Review and Monitoring Committee (PRMC) reviews and prioritizes all cancer-related clinical research handled at Perlmutter Cancer Center and NYU Langone Health. We hold the authority to approve protocols that meet scientific merit and Perlmutter Cancer Center’s scientific priorities and to terminate protocols that do not demonstrate scientific progress. All cancer-related studies are required to be reviewed by our committee prior to study activation. We also determine which studies warrant the use of Clinical Trials Office resources.

PRMC Coordinator

Please contact Sherry Cheng at Sherry.Cheng@NYULangone.org.

For more information about Perlmutter Cancer Center’s Clinical Trials Office, please email CancerTrials@NYULangone.org.

View the Protocol Review and Monitoring Committee membership, learn more about the different steps involved in a typical review and the types of review members perform, and access the meeting schedule and submission deadlines.